<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="209">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 14, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04780334</url>
  </required_header>
  <id_info>
    <org_study_id>2021_0063</org_study_id>
    <secondary_id>2021-A00387-34</secondary_id>
    <nct_id>NCT04780334</nct_id>
  </id_info>
  <brief_title>Rapid Detection of COVID-19 by Portable and Connected Biosensor : Biological Proof of Concept</brief_title>
  <acronym>COR-DIAL-S</acronym>
  <official_title>Rapid Detection of COVID-19 by Portable and Connected Biosensor : Biological Proof of Concept</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Lille</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Lille</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of this CorDial-S proof-of-concept study is to evaluate the ability to&#xD;
      detect COVID-19 infection in nasopharyngeal swabs with CorDial-S and compare it to the PCR&#xD;
      technique currently in use. Saliva analysis will be the subject of secondary analysis.&#xD;
&#xD;
      The CorDial-S medical device could allow the specimens to be analyzed using a small portable&#xD;
      device and the results to be returned in minutes to the medical team and the patient, and&#xD;
      communicated in real time with a telemedicine and remote monitoring system to the health&#xD;
      authorities to allow the necessary protective, containment and therapeutic management&#xD;
      measures to be put in place if necessary.&#xD;
&#xD;
      The benefits would be&#xD;
&#xD;
        1. greater sensitivity&#xD;
&#xD;
        2. a great speed because 8tests could be performed at the same time with a result in a few&#xD;
           minutes&#xD;
&#xD;
        3. a very high specificity at least equivalent to PCR.&#xD;
&#xD;
      This new diagnostic strategy could become extremely valuable in the fight against COVID-19,&#xD;
      especially in the case of very long-term persistence and incomplete vaccination of the French&#xD;
      and foreign population.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 2021</start_date>
  <completion_date type="Anticipated">April 2022</completion_date>
  <primary_completion_date type="Anticipated">April 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Sensitivity and specificity of CorDial-S based on the first nasopharyngeal swab taken on patient admission, compared to the final positive or negative diagnosis of COVID-19 by the medical team</measure>
    <time_frame>at patient admission (Baseline)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cohen's Kappa Coefficient for concordance for the diagnosis of CoV-2-SARS between PCR and CorDial-S based on nasopharyngeal swabs taken at patient admission.</measure>
    <time_frame>at patient admission (Baseline)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sensitivity and specificity of CorDial-S based on the first saliva sample taken at patient admission compared to the final positive or negative diagnosis of COVID-19 by the medical team.</measure>
    <time_frame>at patient admission (Baseline)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cohen's Kappa Coefficient for concordance for the diagnosis of CoV-2-SARS between PCR and CorDial-S based on saliva samples taken at patient admission.</measure>
    <time_frame>at patient admission (Baseline)</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>SARS-CoV Infection</condition>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>Positive diagnosis of SARS-CoV-2</arm_group_label>
    <description>100 patients with a positive diagnosis of SARS-CoV-2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Negative diagnosis of SARS-CoV-2</arm_group_label>
    <description>100 patients with a negative diagnosis of SARS-CoV-2 defined by the gold standard by the medical team</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>COVID-19 RT-PCR</intervention_name>
    <description>Nasopharyngeal swabs for COVID-19 RT-PCR</description>
    <arm_group_label>Negative diagnosis of SARS-CoV-2</arm_group_label>
    <arm_group_label>Positive diagnosis of SARS-CoV-2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Biosensor</intervention_name>
    <description>Portable and Connected Biosensor viral</description>
    <arm_group_label>Negative diagnosis of SARS-CoV-2</arm_group_label>
    <arm_group_label>Positive diagnosis of SARS-CoV-2</arm_group_label>
  </intervention>
  <biospec_retention>None Retained</biospec_retention>
  <biospec_descr>
    <textblock>
      nasopharyngeal swab and saliva&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        patients admitted to a Reference Health Establishment for suspicion of SARS-CoV-2&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female or child without age limit&#xD;
&#xD;
          -  Admitted to a Reference Health Establishment (RHS) in an emergency unit,&#xD;
             hospitalization or intensive care unit for suspicion of SARS-CoV-2 infection&#xD;
             regardless of clinical presentation and degree of severity.&#xD;
&#xD;
          -  Patient to be diagnosed by PCR test on nasopharyngeal swab.&#xD;
&#xD;
          -  Social insured&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Refusal of the person to participate (collection of information, second use of his&#xD;
             sample, collection of saliva by spitting)&#xD;
&#xD;
          -  Pregnant and breastfeeding women&#xD;
&#xD;
          -  Protected Majors&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Enagnon Kazali ALIDJINOU, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Lille</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Enagnon Kazali ALIDJINOU, MD</last_name>
    <phone>0320445962</phone>
    <phone_ext>+33</phone_ext>
    <email>EnagnonKazali.ALIDJINOU@CHRU-LILLE.FR</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>David Devos, MD,PhD</last_name>
    <email>david.devos@chru-lille.fr</email>
  </overall_contact_backup>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 2, 2021</study_first_submitted>
  <study_first_submitted_qc>March 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 3, 2021</study_first_posted>
  <last_update_submitted>March 2, 2021</last_update_submitted>
  <last_update_submitted_qc>March 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronavirus Infections</mesh_term>
    <mesh_term>Severe Acute Respiratory Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

